Overview

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT.

Phase:

Phase 3

Details

Lead Sponsor:

Actelion

Treatments:

1-Deoxynojirimycin
Miglustat